Reason for request
Reassessment
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of LYNPARZA (olaparib), monotherapy, remains substantial in the MA indication.
|
Clinical Added Value
| minor |
In view of:
- the evidence of the superiority of olaparib monotherapy versus placebo, in a randomised double-blind study, in terms of investigator-assessed progression-free survival: HR=0.30 [95%CI: 0.23-0.41], with a median progression-free survival not reached in the olaparib group and of 13.8 months in the placebo group,
- the lack of evidence of superiority on overall survival, despite the new data submitted,
- the lack of formal conclusion that can be drawn from the quality-of-life findings,
- the safety profile of olaparib, with in particular the onset of myelodysplastic syndromes/acute myeloid leukaemia,
the Committee deems that LYNPARZA (olaparib) monotherapy provides minor clinical added value (CAV IV) in the therapeutic strategy.
|
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
fbc2AkGpb9pQcVCd